Characterization and Quantitation of Genotoxic Impurities Using a Single Platform – The Valsartan Case
Who's speaking at this Webinar?
Technical Marketing Manager, SCIEX
This webinar highlights key challenges related to the recent U.S Food and Drug Administration (FDA) recall of several medicines containing Valsartan, following the detection of genotoxic impurities.
Rolf Kern from SCIEX will outline the current situation, explore the analytical methods used to characterize and quantify the impurities, and present a case study describing appropriate LC-MS methodology.
Attend this webinar:
- For insight into the current market situation with regards valsartan recall
- To discover what the analytical method landscape looks like
- To learn how an LC-QTOF based method can be used for both characterization and quantification of valsartan genotoxic impurities.